Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

No Evidence for BRAF-V600E Results From a High-throughput Analysis of 534 Cases Using a Mutation-specific Antibody

No Evidence for BRAF-V600E Results From a High-throughput Analysis of 534 Cases Using a... RESEARCH ARTICLE No Evidence for BRAF-V600E Mutations in Gastroeosophageal Tumors: Results From a High-throughput Analysis of 534 Cases Using a Mutation-specific Antibody Matthias Preusser, MD,*w Anna S. Berghoff, MD,wz David Capper, MD,y8 Andreas von Deimling, MD,y8 Florian Maroske,z Thomas Brodowicz, MD,*w Michael Hejna, MD,*w Peter Birner, MD, MSc,w# and Sebastian F. Schoppmann, MDwz Key Words: BRAF-V600E mutation, upper gastrointestinal tract Background: BRAF-V600E mutations are found in a broad tumor, gastroesophageal tumors, gastric gastrointestinal spectrum of cancer types and can be successfully targeted by stromal tumors, immunohistochemistry, BRAF, v-raf murine specific therapeutic compounds. Little data on the prevalence of sarcoma viral oncogene homolog B1 BRAF-V600E mutations in tumors of the upper gastrointestinal (Appl Immunohistochem Mol Morphol 2013;21:426–430) tract are available. Materials and Methods: We constructed tissue microarrays of formalin-fixed and paraffin-embedded specimens of 534 gastroesophageal tumors (119 squamous cell cancers and 72 astroesophageal cancers are among the 10 leading adenocarcinomas of the esophagus, 63 cancers of the gastro- Gcauses of cancer-related death worldwide and the esophageal junction/cardia, 199 gastric cancers of the corpus or incidence is significantly increasing. Standard therapy antrum, 81 gastric gastrointestinal stromal tumors) and per- options include endoscopic or surgical resection, radio- formed anti-BRAF-V600E immunostaining using the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

No Evidence for BRAF-V600E Results From a High-throughput Analysis of 534 Cases Using a Mutation-specific Antibody

Loading next page...
 
/lp/wolters-kluwer-health/no-evidence-for-braf-v600e-results-from-a-high-throughput-analysis-of-rmxwC5QrcO

References (34)

Copyright
Copyright © 2013 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0b013e31827ce693
pmid
23343956
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE No Evidence for BRAF-V600E Mutations in Gastroeosophageal Tumors: Results From a High-throughput Analysis of 534 Cases Using a Mutation-specific Antibody Matthias Preusser, MD,*w Anna S. Berghoff, MD,wz David Capper, MD,y8 Andreas von Deimling, MD,y8 Florian Maroske,z Thomas Brodowicz, MD,*w Michael Hejna, MD,*w Peter Birner, MD, MSc,w# and Sebastian F. Schoppmann, MDwz Key Words: BRAF-V600E mutation, upper gastrointestinal tract Background: BRAF-V600E mutations are found in a broad tumor, gastroesophageal tumors, gastric gastrointestinal spectrum of cancer types and can be successfully targeted by stromal tumors, immunohistochemistry, BRAF, v-raf murine specific therapeutic compounds. Little data on the prevalence of sarcoma viral oncogene homolog B1 BRAF-V600E mutations in tumors of the upper gastrointestinal (Appl Immunohistochem Mol Morphol 2013;21:426–430) tract are available. Materials and Methods: We constructed tissue microarrays of formalin-fixed and paraffin-embedded specimens of 534 gastroesophageal tumors (119 squamous cell cancers and 72 astroesophageal cancers are among the 10 leading adenocarcinomas of the esophagus, 63 cancers of the gastro- Gcauses of cancer-related death worldwide and the esophageal junction/cardia, 199 gastric cancers of the corpus or incidence is significantly increasing. Standard therapy antrum, 81 gastric gastrointestinal stromal tumors) and per- options include endoscopic or surgical resection, radio- formed anti-BRAF-V600E immunostaining using the

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Oct 1, 2013

There are no references for this article.